RCS - hVIVO PLC - COVID-19 study published in Nature Communications

hVIVOAnnouncement

12/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241212:nRSL7038Pa&default-theme=true

RNS Number : 7038P  hVIVO PLC  12 December 2024

hVIVO plc

("hVIVO", the "Company" or the "Group")

 

COVID-19 characterisation study published in peer-reviewed Nature
Communications

 

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation
(CRO) and world leader in testing infectious and respiratory disease products
using human challenge clinical trials, announces that an additional
peer-reviewed paper from the world's first COVID-19 characterisation trial has
been published in Nature Communications.

 

"SARS-CoV-2 human challenge reveals single-gene blood transcriptional
biomarkers that discriminate early and late phases of acute respiratory viral
infections", by Rosenheim, J. et al. is available in Nature Communications,
https://www.nature.com/articles/s41467-024-54764-3
(https://www.nature.com/articles/s41467-024-54764-3) DOI:
https://doi.org/10.1038/s41467-024-54764-3
(https://doi.org/10.1038/s41467-024-54764-3)

 

The study identified key blood-based biomarkers activated, not only in
SARS-CoV-2 infection but also in other respiratory viruses, that can identify
and distinguish between the early and late phases of infection. These
biomarkers could provide a basis for advancements in infection diagnosis and
management in early and late-stage infections.

 

The SARS-CoV-2 characterisation study was conducted by hVIVO, in partnership
with Imperial College London, the Vaccine Taskforce and Department of Health
and Social Care (DHSC) and the Royal Free London NHS Foundation Trust. The
study showed that the SARS-CoV-2 human challenge was safe in healthy young
adults and provided detailed insights into the course of COVID-19 infection
with potential positive public health implications. The clinical results of
the study were published previously in Nature Medicine in March 2022.

 

Nature Communications is an open access, multidisciplinary journal dedicated
to publishing high-quality research in all areas of the biological, health,
physical, chemical, Earth, social, mathematical, applied, and engineering
sciences. Papers published by the journal aim to represent important advances
of significance to specialists within each field.

 

Dr Andrew Catchpole, Chief Scientific Officer of hVIVO plc, said: "Human
challenge trials allow researchers to observe in detail infection progression,
particularly in the early stages, that would not be possible with a
traditional field study. It is fantastic to see that our original COVID-19
viral characterisation study is continuing to enhance understanding of the
immune response to SARS-CoV-2 infection and other respiratory viruses, and to
see the findings published in a prestigious journal such as Nature
Communications.

 

"Excitingly, the early-stage marker was observable sometimes even before PCR
testing confirmed the presence of the virus, suggesting future clinical
utility in inferring the infectiousness of a patient early in the infection
time-course as well as a potential role in helping stratify patients for
antiviral therapy."

 

For further information please contact:

 

 hVIVO plc                                       +44 (0)20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)                  +44 (0)20 7220 0500
 Geoff Nash, Camilla Hume, Harriet Ward

 Nigel Birks - Life Science Specialist Sales

 Louise Talbot - Sales

 Peel Hunt LLP (Joint Broker)                                        +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Euronext Growth Adviser and Joint Broker)                     +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 Walbrook PR (Financial PR & IR)                 +44 (0)20 7933 8780 or hvivo@walbrookpr.com

 Paul McManus / Phillip Marriage /               +44 (0)7980 541 893 / +44 (0)7867 984 082 /

Louis Ashe-Jepson
+44 (0)7747 515 393

 

 

Notes to Editors

 

hVIVO plc (http://www.hvivo.com) (ticker: HVO) is a fast-growing specialist
contract research organisation (CRO) and the world leader in testing
infectious and respiratory disease vaccines and therapeutics using human
challenge clinical trials. The Group provides end-to-end early clinical
development services to its large, established and growing repeat client base,
which includes four of the top 10 largest global biopharma companies.

 

The Group's fast-growing services business includes a unique portfolio of 11
human challenge models, with a number of new models under development, to test
a broad range of infectious and respiratory disease products. The Group has
world class challenge agent manufacturing capabilities, specialist drug
development and clinical consultancy services via its Venn Life Sciences
brand, and a lab offering via its hLAB (https://hlabservices.com/) brand,
which includes virology, immunology biomarker and molecular testing. The Group
also offers additional clinical field trial services such as patient
recruitment and clinical trial site services.

 

hVIVO runs challenge trials in London - its new state-of-the-art facilities
in Canary Wharf opened in 2024 and is the world's largest commercial human
challenge trial unit, with highly specialised on-site virology and immunology
laboratories, and an outpatient unit. To recruit volunteers / patients for its
studies, the Group leverages its unique clinical trial recruitment capability
via its FluCamp (http://www.flucamp.com/) volunteer screening facilities
in London and Manchester.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAEAFFLXLFFA